Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 6—June 2025
Research
Diagnostic Accuracy of 3 Mpox Lateral Flow Assays for Antigen Detection, Democratic Republic of the Congo and United Kingdom
Table 1
Clinical characteristics of recruited mpox patients in study of diagnostic accuracy of 3 mpox lateral flow assays for antigen detection, Democratic Republic of the Congo and United Kingdom*
Characteristic | Democratic Republic of the Congo, n = 68 | United Kingdom, n = 16 |
---|---|---|
Mean age (range), y |
17 (2–47) |
35.1 (24–58) |
Sex | ||
M | 34 (50) | 16 (100) |
F |
34 (50) |
0 |
Time from symptom onset, d | ||
Median (interquartile range) | 4 (3–7) | 8 (4.25–12.75) |
0–3 | 32 (47) | 1 (6.25) |
4–7 | 22 (32) | 6 (37.5) |
>8 |
14 (21) |
9 (56.25) |
Symptoms | ||
Skin lesions | 68 (100) | 16 (100) |
Fever | 62 (91) | 11 (68.75) |
Influenza-like symptoms | 51 (75) | 4 (25) |
Skin rashes | 0 | 14 (87.5) |
Headache | 37 (54) | 4 (25) |
Cough | 34 (50) | 1 (6.25) |
Sore throat | 25 (37) | 4 (25) |
Nausea | 20 (29) | 0 |
Abdominal pain | 19 (28) | 0 |
Chest pain | 14 (21) | 0 |
Vomiting | 6 (9) | 0 |
Diarrhea | 5 (7) | 1 (6.25) |
Painful Urination | 4 (6) | 0 |
Eye discharge | 3 (4) | 0 |
Redness of eyes | 2 (3) | 0 |
*Values are no. (%) except as indicated.
1These authors contributed equally to this article.
2Members of ISARIC 4C investigator group are listed at the end of this article.
Page created: April 08, 2025
Page updated: May 02, 2025
Page reviewed: May 02, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.